Aldeyra Therapeutics, Inc.ALDXNASDAQ

Revenue (LTM)

Net Income (LTM)

$-34M

+39.4% YoY

Free Cash Flow

$-33.3T

Revenue CAGR (5Y)

—

—Marginsstable

FCF($33345.7B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	0	0	0
Gross Profit	0	0	0	0	-0
Operating Income	-56	-63↓11.5%	-43↑31.7%	-60↓40.5%	-35↑41.3%
Net Income	-58	-62↓7.4%	-38↑39.5%	-56↓48.8%	-34↑39.4%
EBITDA	-56	-60↓7.7%	-35↑41.4%	-54↓52.5%	-32↑41.0%
EPS Diluted	-1.07	-1.06↑0.9%	-0.64↑39.6%	-0.94↓46.9%	-0.56↑40.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	230	144↓37.2%	143↓1.1%	55↓61.8%	70,041,254↑128452108.7%
Total Current Assets	233	181↓22.2%	148↓18.3%	104↓29.6%	71,783,456↑68974385.3%
Total Assets	233	181↓22.2%	148↓18.2%	105↓29.5%	72,059,317↑68885852.0%
Total Current Liabilities	12	15↑30.5%	22↑44.9%	19↓16.4%	27,808,927↑149495608.0%
Total Liabilities	27	30↑10.5%	29↓5.8%	34↑17.8%	27,808,927↑82760073.5%
Total Equity	206	151↓26.6%	120↓20.7%	71↓40.7%	44,250,390↑62320117.4%
Total Debt	16	16↑1.4%	16↓2.7%	15↓2.3%	15,530,169↑101484353.7%
Net Debt	-214	-128↑40.0%	-127↑0.9%	-39↑69.2%	-54,511,085↓138973389.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-43	-57↓33.1%	-30↑46.5%	-43↓42.5%	-33,345,682↓77173352.9%
Capital Expenditure	-0	-0↓109.0%	0	0	0
Free Cash Flow	-43	-57↓33.1%	-30↑46.5%	-43↓42.5%	-33,345,682↓77173352.9%
Stock-Based Comp	7	8↑16.6%	6↓30.6%	8↑38.6%	6,091,413↑76395632.9%
Net Change in Cash	152	-85↓156.2%	-2↑98.1%	-88↓5431.1%	15,514,162↑17570743.5%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance